Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-10-29; most recent amendment 2026-05-26.
Status change: Not Yet Recruiting → Recruiting 2025-12-16
Trial Details
NCT Number NCT07223047
Lead Sponsor Bristol-Myers Squibb
Conditions Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment 252 participants
Start Date 2025-11-25
Primary Completion 2028-10-13 (estimated)
Study Completion 2028-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-05-28